 "Employees of Biocon Ltd work inside the company's research and development centre in Bengaluru. File photo: Reuters")
Biotechnology major Biocon is aiming to register a 66 per cent growth in its biologics business this fiscal, which the company hopes will help it clock a revenue of $200 million on the back of emerging markets growth.
Its current revenue from the biosimilars market is around $120 million. In the last six months, the company (along with its partner Mylan) has made significant progress on the regulatory front in the US and EU markets and has built a biosimilars pipeline. However, it is still some time away for these markets to drive growth. The company feels that developed markets would
